The data indicating that increased IGFBP5 is correlated with decreased overall survival in ovarian (62), breast (69) and other cancers (125) contrasts with the many in vitro and in vivo studies suggesting a tumor-suppressor function. Here, IGFBP5 is linked to cancer.